Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: Comparison with standard 4/2 schedule.

Kojiro OhbaYasuyoshi MiyataTakuji YasudaAkihiro AsaiKensuke MitsunariTomohiro MatsuoYasushi MochizukiNoriko MatsunagaHideki Sakai

Published in: Asia-Pacific journal of clinical oncology (2018)

Sunitinib administered q.a.d. was safe and effective for mRCC patients. We speculate that the persistent optimal drug plasma concentrations contributed to these effects.

Keyphrases

metastatic renal cell carcinoma
end stage renal disease
newly diagnosed
chronic kidney disease
renal cell carcinoma
prognostic factors
peritoneal dialysis
patient reported outcomes
patient reported